Here’s Why Azenta (AZTA) Performed Well in the Second Quarter

Polen Capital, an investment management company, released its “Polen U.S. Small Company Growth Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund returned -25.81% net of fees compared to a -19.25% return for the Russell 2000 Growth Index. The fund underperformed in the second quarter due to widespread economic slowdown. In addition, please check the fund’s top five holdings to know its best picks in 2022.

In the second quarter 2022 investor letter, Polen Capital discussed stocks like Azenta, Inc. (NASDAQ:AZTA). Headquartered in Chelmsford, Massachusetts, Azenta, Inc. (NASDAQ:AZTA) is a life science solution provider. On November 04, 2022, Azenta, Inc. (NASDAQ:AZTA) stock closed at $42.07 per share. One-month return of Azenta, Inc. (NASDAQ:AZTA) was 4.13% and its shares lost -66.50% of their value over the last 52 weeks. Azenta, Inc. (NASDAQ:AZTA) has a market capitalization of $3.298 billion.

Here is what Polen Capital specifically said about Azenta, Inc. (NASDAQ:AZTA) in its Q2 2022 investor letter:

Azenta, Inc. (NASDAQ:AZTA) is a health care company that focuses on biological sample management. The company, previously known as Brooks Automation, re-branded as Azenta after selling its semiconductor business earlier this year. The company is the only end-to-end provider of reliable cold-chain sample management solutions and genomic services and benefits from the trend towards sample outsourcing by pharmaceutical and diagnostic companies.”

Tonhom1009/Shutterstock.com

Azenta, Inc. (NASDAQ:AZTA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held Azenta, Inc. (NASDAQ:AZTA) at the end of the second quarter which was 25 in the previous quarter.

We discussed Azenta, Inc. (NASDAQ:AZTA) in another article and shared the best automation stocks to buy. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.